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The guidelines for follow-up of breast cancer patients concentrate on the first 3–5 years, with either reduced frequency of visits or
discharge after this. They also recommend mammography, but no evidence exists to inform frequency. We analyse treatable relapses
in our unit from 1312 patients with early stage breast cancer treated by breast conserving surgery (BCS) and postoperative
radiotherapy between 1991 and 1998 to assess appropriateness of the guidelines. A total of 110 treatable relapses were analysed.
Treatable relapse developed at 1–1.5% per year throughout follow-up. Forty-eight relapses were in ipsilateral breast, 25 ipsilateral
axilla, 35 contralateral breast, 2 both breasts simultaneously. Thirty-seven relapses (33.5%) were symptomatic, 56 (51%)
mammographically detected, 15 (13.5%) clinically detected, 2 (2%) diagnosed incidentally. Mammography detected 5.37 relapses per
1000 mammograms. Patients with symptomatic or mammographically detected ipsilateral breast relapse had significantly longer
survival from original diagnosis (P¼0.0002) and from recurrence (P¼0.0014) compared with clinically detected. Treatable relapse
occurs at a constant rate for at least 10 years. Clinical examination detects a minority (13.5%). Relapse diagnosed clinically is
associated with poorer outcome. Long-term follow-up based on regular mammography is warranted for all patients treated by BCS.
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Historically, follow-up in breast cancer has focused on the early
detection of relapse. The approach to detecting locoregional and
metastatic relapse has changed as understanding of the natural
history of the disease has improved. The diagnosis of incurable
metastatic disease when patients are still asymptomatic does not
significantly alter outcome (Del Turco et al, 1994; The GIVIO
investigators, 1994). Moreover, regular visits are likely to increase
distress and reduce quality of life, and may lead to unnecessary
treatment (Del Turco et al, 1994; The GIVIO investigators, 1994).
Tests to detect metastatic disease are no longer recommended
(National Institute for Clinical Excellence, 2002).
Unlike metastatic relapse, it is generally accepted that,
particularly in patients who have had breast-conserving surgery,
locoregional relapse is potentially treatable and should be detected
early (Clark et al, 1985; Recht et al, 1989; Fowble et al, 1990; Kurtz
et al, 1990; Haffty et al, 1991; Dalberg et al, 1998). Regular periodic
mammography and clinical examination are performed to detect
asymptomatic ipsilateral and contralateral disease. However, in a
recent meta-analysis routine clinic visits were at best inefficient in
the detection of treatable locoregional relapse (de Bock et al, 2004).
We have previously reported that only one-third of these are
detected by clinicians at routine visits in asymptomatic patients,
representing one relapse detected for every 175 routine clinic visits
(Jack et al, 1998). Despite locoregional relapse being relatively rare,
and most such relapses being detected by other means, many
clinicians still consider routine clinical examination necessary
for detection of relapse. Increasingly, less frequent or shorter
follow-up is being advised in an attempt to improve efficiency.
While reduced follow-up has been shown to be acceptable to
patients (Gulliford et al, 1997), little is known of its impact on
loco-regional relapse detection and overall survival.
We have examined the pattern of treatable relapse in our unit,
particularly with regard to its timing and method of detection,
relating our findings to current guidelines to highlight their likely
effect on our patients.
PATIENTS AND METHODS
Between 1991 and 1998, 1312 patients were treated for early stage
breast cancer by breast conservation surgery, axillary node
sampling or clearance and postoperative radiotherapy to the
breast þ/  ipsilateral lymphatics. Systemic therapy was given
according to local and national guidelines. Follow-up was shared
between the Edinburgh Breast Unit and the Department of Clinical
Oncology, Western General Hospital, Edinburgh.
Although initial clinical follow-up consisted of 3–4 monthly
visits for the first 2 years, 6 monthly for 3 years then annual visits
until the tenth anniversary, from 2000, all patients were changed
to annual follow-up visits only. Throughout, all patients were
instructed in regular breast self-examination. Additional interval
Received 22 January 2007; revised 25 April 2007; accepted 1 May 2007;
published online 29 May 2007
*Correspondence: DA Montgomery;
E-mail: davidandrewmontgomery@hotmail.com
British Journal of Cancer (2007) 96, 1802–1807
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
svisits for assessment were arranged by patients, their general
practitioner or other health-care professionals as required. Patients
were usually discharged to the national breast screening unit at 10
years. Annual bilateral mammography was undertaken through-
out. Median follow-up was 10 years, range 1.5–15 years.
Characteristics of the included patients are presented in Table 1.
Locoregional relapse was defined as any relapse in the ipsilateral
breast and axilla or the contralateral breast. Contralateral breast
cancers are included here as the risk of subsequent contralateral
breast cancer in patients who have had a previous breast cancer is
3–5 times greater than the population risk (Mellink et al, 1991).
As such, detecting new contralateral cancers is an important
component of breast cancer follow-up programmes. Supraclavi-
cular relapse was included with metastatic disease. Detection of
metastatic disease within 3 months of locoregional relapse was
considered to constitute simultaneous local and distant relapse and
these patients were excluded from the analysis.
A list of all patients known to have suffered an isolated
locoregional relapse or new contralateral cancer was generated
from our database in January 2006. A retrospective study of these
case records was then undertaken. Time from diagnosis to relapse,
method of detection of relapse (routine mammography, routine
clinical examination in an asymptomatic patient or investigation of
a patient who attended complaining of relevant symptoms) and
type of clinic (routine or interval) was recorded. Time from relapse
to development of metastatic disease or death was then calculated
and survival was compared for each mode of detection. For all
relapses detected clinically in the first instance, we established
whether the relapse was also visible on mammography.
RESULTS
Between 1991 and 1998, 1312 patients were treated for primary
operable breast cancer by breast conservation surgery. Figure 1
displays overall survival, Figure 2 cause specific survival. The
overall 5-year survival was 89.2%; 10-year survival was 77.2%. Not
included in the analysis were 31 patients with synchronous
locoregional and metastatic disease and 11 with metastatic disease
before locoregional relapse; these are included as metastatic
relapse in Figure 3 (see below). A total of 116 patients suffered
an isolated locoregional relapse. After exclusion of four lacking
available records, and two lost to follow-up through moving away
from the area, 110 patients were left for analysis. Details of all
patients with treatable relapse are shown in Table 2.
48 patients developed ipsilateral breast relapse, 11 with
concomitant axillary disease. Twenty-five patients had isolated
ipsilateral axillary relapse and 35 developed new contralateral
cancers. One patient developed ipsilateral breast and axillary
relapse and a new contralateral cancer simultaneously and one
developed ipsilateral breast relapse and a new contralateral cancer
simultaneously.
The recurrence rate in this cohort is presented as Figure 3. The
incidence of metastatic relapse peaks at just over 3% per annum at
2–3 years and remains above 2% per year for up to 5 years before
falling off. In contrast, the incidence of locoregional relapse
remains constant at 1–1.5% over the whole follow-up period.
Site of relapse and method of detection are summarised for the
110 patients in Table 3, together with the numbers who died (in
brackets).
Interval appointments
Twenty-three of the 110 patients (21%) had relapse detected at an
interval clinic visit of whom 22 complained of relevant symptoms,
and the other had an abnormality noticed by careers. Of these 23
patients, 10 had ipsilateral breast relapse, 6 axillary relapse and 2
had synchronous breast and axillary relapse, with symptoms from
both sites. Five patients discovered their new contralateral cancer.
Two patients (2%) were referred back to clinic having been
discharged from further follow-up at 10 years post-treatment. One
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Figure 1 Overall survival.
Table 1 Study population
Age (years)
Mean 56 years
Range 24–91 years
Tumour stage No. of patients
T1 725
T2 587
Node status No. of patients
Positive 354
Negative 958
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scomplained of symptoms related to axillary relapse (included in
Table 3 as having been diagnosed at an interval clinic with
symptoms) and one had abnormal routine breast screening
mammograms, which indicated breast and axillary relapse (included
in Table 3 as routine mammographically detected relapse).
Routine appointments
The remaining 85 relapses (77%) were detected at routine clinics
or by routine mammography. The pattern of relapse and method
of detection for this group is also presented in Table 3.
Of the four ipsilateral breast recurrences diagnosed clinically,
the most recent annual surveillance mammogram was negative in
two. Mammography was repeated and was negative in the third.
In the fourth, mammography did reveal some distortion, but this
was reported as benign post-surgical changes in their first routine
follow-up mammogram 1 year after surgery. Neither of the two
contralateral cancers detected clinically were visible on mammo-
graphy. Of the nine axillary relapses diagnosed clinically, one also
visible on mammography was included as a clinical diagnosis as it
was diagnosed at a routine appointment at which mammography
was not scheduled.
In total, 37 relapses (33.5%) were symptomatic, 56 (51%)
mammographically detected, 15 (13.5%) clinically detected and 2
(2%) were diagnosed incidentally.
A total of 10415 mammograms were undertaken during follow-
up, with 56 treatable relapses diagnosed that is 5.37 treatable
relapses per 1000 mammograms.
Survival
Details of the 37 deaths among the 110 patients during the follow-
up period are shown in Table 3.
Ipsilateral breast Forty-eight patients suffered ipsilateral breast
recurrence, of whom 11 had additional axillary recurrence. Overall
5-year survival was 87.5% from original operation, and 64% from
diagnosis of recurrence. Survival by method of detection is shown
below (Figure 4).
Overall survival was significantly reduced among those with
recurrence diagnosed clinically compared with either other
method (log rank 2df P¼0.0002). This remains highly significant
even if cases with axillary disease are excluded (P¼0.0004), and
reflects a significantly longer survival from recurrence (Figure 5)
(log rank 2df P¼0.0014) rather than a difference in time to
recurrence detection.
The pathological characteristics of the recurrent disease are
presented as Table 4. Mean age at recurrence is also shown. Nodal
status was available for all 48 patients. Size of the recurrent lesion
was unavailable for 10 women, with grade of the recurrence
unavailable for 13. Receptor status was seldom available. Trends
for those with clinically detected relapse to be older than others,
and for mammographically detected lesions to be smallest at
detection, with symptomatic largest, were not significant. Overall,
there was no significant difference in any of the clinicopathological
features in relation to how relapse was detected, and Nottingham
Prognostic Index of the relapse was similar for all three groups.
Contralateral breast There was no association between method
of detection of relapse and survival in patients who developed a
new contralateral breast cancer. However, 25 out of 35 of these
(71%) were diagnosed by mammography with 8 self-diagnosed and
2 picked up on clinical examination. Both of the patients with new
cancers detected clinically were well at last follow-up. Overall 5-
year survival from time of relapse for all patients with contralateral
breast relapse was 81%.
Table 3 Pattern of relapse and detection
Site of relapse Symptoms Clinical finding Mammogram Interval clinic with symptoms Total
Ipsilateral Breast 5 (1) 3 (3) 18 (5) 10 (3) 36 (12)
Ipsilateral Axilla 5 (5) 9 (3) 4 (1) 7 (2) 25 (11)
Ipsilateral breast and axilla 0 (0) 1 (1) 7 (1) 2 (1) 10 (3)
Contralateral breast 3 (2) 2 (0) 25 (5) 5 (1) 35 (8)
Ipsilateral axilla and bilateral breast 0 0 1 (0) 0 1 (0)
Bilateral breast 0 0 1 (1) 0 1 (1)
Total 13 (8) 15 (7) 56 (13) 24 (7) 108 (35)
The number of patients who subsequently died is included in brackets. Two patients, not included in this table, had ipsilateral breast relapse, one node positive, diagnosed
incidentally during breast reshaping procedures. Both of these patients subsequently died.
Table 2 Study population, original pathology
Age (years)
Mean 54.28 (s.d. 12.32)
Range 24–83
Tumour stage No. of patients
T1 67 (inc. 1 bilateral)
T2 46
Node status No. of patients
Positive 29
Negative 84 (inc. 1 bilateral)
1.0
0.8
0.6
0.4
0.2
0.0
20 40
Time (months)
S
u
r
v
i
v
a
l
60 80 100 120 140 160 180 200
Method of detection
clinical
censored
mammographic
censored
censored
symptomatic
Figure 4 Survival from original operation in patients with ipsilateral
breast relapse.
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sIpsilateral axilla There was similarly no association between
method of detection of recurrence and survival in patients who had
isolated ipsilateral axillary relapse, although the numbers overall
were small. Overall 5-year survival from time of relapse for
patients with axillary relapse was 61%.
DISCUSSION
The most recent guidelines for the follow-up of breast cancer
patients from the American Society of Clinical Oncology (ASCO)
recommend 3–6 monthly follow-up for 3 years, 6–12 monthly for
2 years then annual follow-up (Khatcheressian et al, 2006). No
advice is given regarding discharge, although 1999 guidelines
recommended this at 10 years (American Society of Clinical
Oncology, 1999). In Canada, the Steering Committee guidelines
state that there is no compelling evidence to support any particular
frequency of clinic visits, but concludes that visits should be more
frequent initially due to a higher risk of recurrence in the first few
years, reducing to annual after 3–5 years and being continued
indefinitely (The Steering Committee on Clinical Practice Guide-
lines for the Care and Treatment of Breast Cancer, 1998). Annual
mammography is recommended by both groups, although ASCO
acknowledge the lack of good evidence (Khatcheressian et al,
2006).
In contrast, the recent guidelines for England and Wales (NICE)
recommend follow-up of only 2–3 years in total, but leave
frequency of visits open (National Institute for Clinical Excellence,
2002). The British Association of Surgical Oncology (BASO)
recommends slightly longer follow-up, with discharge at 5 years,
again leaving frequency of visits open (The Association of Breast
Surgery @ BASO and Royal College of Surgeons of England, 2005).
Neither group recommends how often mammography should be
performed, with NICE stating that evidence-based protocols
should be agreed locally, and BASO referring to the Royal College
of Radiologists advice that mammography should be every 1–2
years (The Royal College of Radiologists, 1995).
Although these guidelines appear to vary markedly, all assume
that relapse is commonest in the first few years after treatment. A
greater hazard rate for relapse during the first 3 years was just
evident in the ATAC trial (The ATAC Trialists’ Group, 2005), but
reflects a higher rate of distant relapse in this period. Others have
reported that the rate of locoregional relapse is initially high, and
then falls off, so that most treatable relapses occur in the first 3–5
years (Elder et al, 2006). However, these studies do not include
new contralateral cancers. Other studies have a very brief median
follow-up, without analysis of recurrence over the long term
(Donnelly et al, 2001). The present study confirms that rate of
distant relapse peaks in the first 5 years, but this is not mirrored by
the pattern of locoregional relapse, which remains constant at 1–
1.5% for at least 10 years. Others have also reported that while the
incidence of true local recurrence declines with time, that of new
breast cancers in other areas of the previously treated breast and
new contralateral breast cancers increases with time, so that the
overall rate of treatable relapse remains constant for over 15 years
(Freedman et al, 2005).
The second assumption in various guidelines is that clinical
examinations are of particular value, with more frequent visits
recommended during the perceived high-risk period of the first
few years. Previous studies have consistently shown that multiple
clinical visits do little to increase yield and only serve to reduce the
‘cost effectiveness’ of follow-up (de Bock et al, 2004). Our data
confirm this. In 10 years of follow-up in 1312 women, only 15
relapses were detected clinically. This is a very low yield.
Mammography in contrast makes a much larger and more
significant contribution to relapse detection, not only in the area
of contralateral new breast cancer detection but also in detecting
ipsilateral breast recurrence. In fact, a detection rate of 5.37
cancers per 1000 mammograms is higher than that reported as
recently as 2003 by the breast screening service in the UK that
carries out 3-yearly mammography (NHS Cancer Screening
Programmes, 2003), and is equivalent to that in this body’s latest
(2007) report.
Why patients with clinically detected relapse do less well is
unclear from this study, and although slightly older on average, the
difference was not significant. Nottingham Prognostic Index for
the relapse was similar for all three methods of detection.
Our data reveal that the basic assumptions behind the guidelines
for follow-up are incorrect. If a central aim is the detection of
treatable relapse, as stated in the guidelines, there is no
justification for focussing on the first 2–3 years after treatment;
treatable relapse occurs at a constant rate over at least 10 years.
Our data suggest that clinical examinations do not improve
outcome. Women are well schooled in self-surveillance of their
breasts. Axillary relapse, on the contrary, is more frequently
detected by clinicians, 36% being so detected. However, isolated
axillary relapse was relatively rare, with just 25 in 1312 patients
over 10 years, and only nine clinically detected relapses. We intend
to highlight the need for regular axillary self-examination, not
Table 4 Clinicopathological features of recurrence by method of
detection
Symptoms Clinical finding Mammography
Age of patient at relapse
57.7 (s.d. 14.7 years) 62.77 (s.d. 17.7) 59.74 (s.d. 11.8)
Mean size of relapse (mm)
25.85 (s.d. 26.38) 17.67 (s.d. 10.97) 12.71 (s.d. 8.53)
Grade of relapse
Grade 3: 9 Grade 3: 5 Grade 3: 2
Grade 2: 2 Grade 2: 10 Grade 2: 0
Grade 1: 2 Grade 1: 3 Grade 1: 1
Missing: 4 Missing: 7 Missing: 1
Proportion of relapses with positive lymph nodes
2 of 17 (8.5%) 1 of 4 (25%) 7 of 25 (28%)
Mean NPI
a of recurrence
4.36 (s.d. 1.33) 4.02 (s.d. 1.26) 3.87 (s.d. 1.16)
aNPI¼Nottingham Prognostic Index.
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Figure 5 Survival from time of relapse in patients with ipsilateral breast
relapse.
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spreviously stressed, and hope this will further improve the yield of
self-examination, particularly in this era of sentinel lymph node
biopsy.
Detection of treatable relapse is only one of the aims of follow-
up. Additional aims concern psychological problems and adverse
effects of therapy, particularly lymphoedema (National Institute
for Clinical Excellence, 2002). It is uncertain whether routine clinic
visits achieve these aims. While women do find clinics reassuring
when told they do not have recurrence (Morris et al, 1992; Kiebert
et al, 1993), visits are also attended by great anxiety (Paradiso et al,
1995). There is little doubt that clinicians are not good at detecting
psychological problems in the clinical setting (Hardman et al,
1989; Passik et al, 1998) and patients are reluctant to report such
psychological problems themselves (Valente et al, 1994; Pennery
and Mallet, 2000). Certainly, one study has shown no reduction in
quality of life among women randomised to receive no routine
clinic visits compared with regular visits (Gulliford et al, 1997).
Whether routine clinics are necessary for the detection and
treatment of adverse effects of therapy is also uncertain. Detection
of lymphoedema is given central importance in the NICE
guidelines, although its symptoms do not correlate with objective
measurements of arm swelling (Schunemann and Willich, 1998).
Moreover, there is little in the way of an effective therapy. Side
effects of treatment might be detected better by education and
focussing follow-up on the symptomatic individual.
Aromatase inhibitors have introduced a new consideration in
follow-up. The NICE guidelines only mention adjuvant hormonal
therapy to say that the general practitioner should be responsible
for stopping it at 5 years (National Institute for Clinical Excellence,
2002). With recent indications for switch and extended aromatase
treatments, which are instituted in specialist care, discharge to
general practice after 3 years would not be appropriate. Moreover,
hormonal therapy can significantly impact patients’ overall well
being, particularly in the first 3 months of therapy (Fallowfield
et al, 2004). Patients should have access to specialist advice to help
ameliorate any symptoms. Long-term rapid and flexible access to
specialist care would be ideal in the face of new developments in
breast cancer treatment, and emphasis should be placed on
psychological and physical well-being. It is also likely that new
hormonal therapies will alter the pattern of relapse so that even
fewer relapses occur in the first 3 years after treatment (The ATAC
Trialists’ Group, 2005).
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